{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:07:51Z","timestamp":1774314471573,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-025-05987-w","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:08:48Z","timestamp":1767629328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report: Guillain-Barr\u00e9 syndrome probably associated with TNF inhibitor in Blau syndrome"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiqiong","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanliang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"5987_CR1","doi-asserted-by":"publisher","first-page":"988862","DOI":"10.3389\/fimmu.2022.988862","volume":"13","author":"L Mao","year":"2022","unstructured":"Mao L, Dhar A, Meng G, Fuss I, Montgomery-Recht K, Yang Z, Xu Q, Kitani A, Strober W. Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function. Front Immunol. 2022;13:988862. https:\/\/doi.org\/10.3389\/fimmu.2022.988862.","journal-title":"Front Immunol"},{"key":"5987_CR2","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/annrheumdis-2020-217320","volume":"79","author":"T Matsuda","year":"2020","unstructured":"Matsuda T, Kambe N, Ueki Y, Kanazawa N, Izawa K, Honda Y, Kawakami A, Takei S, Tonomura K, Inoue M, Kobayashi H, Okafuji I, Sakurai Y, Kato N, Maruyama Y, Inoue Y, Otsubo Y, Makino T, Okada S, Kobayashi I, Yashiro M, Ito S, Fujii H, Kondo Y, Okamoto N, Ito S, Iwata N, Kaneko U, Doi M, Hosokawa J, Ohara O, Saito MK, Nishikomori R. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis. 2020;79:1492\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217320.","journal-title":"Ann Rheum Dis"},{"key":"5987_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-019-2017-5","volume":"21","author":"J Chen","year":"2019","unstructured":"Chen J, Luo Y, Zhao M, Wu D, Yang Y, Zhang W, Shen M. Effective treatment of TNF\u03b1 inhibitors in Chinese patients with Blau syndrome. Arthritis Res Ther. 2019;21:236. https:\/\/doi.org\/10.1186\/s13075-019-2017-5.","journal-title":"Arthritis Res Ther"},{"key":"5987_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/mus.20924","volume":"37","author":"JP St\u00fcbgen","year":"2008","unstructured":"St\u00fcbgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281\u201392. https:\/\/doi.org\/10.1002\/mus.20924.","journal-title":"Muscle Nerve"},{"key":"5987_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","volume":"165","author":"H Radner","year":"2015","unstructured":"Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015;165:3\u20139. https:\/\/doi.org\/10.1007\/s10354-015-0344-y.","journal-title":"Wien Med Wochenschr"},{"key":"5987_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/ard.2005.043208","volume":"67","author":"S Silburn","year":"2008","unstructured":"Silburn S, McIvor E, McEntegart A, Wilson H. Guillain-Barr\u00e9 syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis. 2008;67:575\u20136. https:\/\/doi.org\/10.1136\/ard.2005.043208.","journal-title":"Ann Rheum Dis"},{"key":"5987_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s10067-017-3573-1","volume":"36","author":"S Psarelis","year":"2017","unstructured":"Psarelis S, Hajineocli APD, Hadjicosta E, Elliott HSA, Johnson P. Is Secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barr\u00e9 syndrome after anti-TNF-\u03b1 treatment? Case report and literature review. Clin Rheumatol. 2017;36:1197\u20139. https:\/\/doi.org\/10.1007\/s10067-017-3573-1.","journal-title":"Clin Rheumatol"},{"key":"5987_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ophtha.2022.03.014","volume":"129","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Ding J, Su G, Liao W, Gao Y, Zhu Y, Deng Y, Li F, Du L, Gao Y, Yang P. Genetic and clinical features of Blau syndrome among Chinese patients with uveitis. Ophthalmology. 2022;129:821\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2022.03.014.","journal-title":"Ophthalmology"},{"key":"5987_CR9","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/art.24533","volume":"60","author":"CD Ros\u00e9","year":"2009","unstructured":"Ros\u00e9 CD, Ar\u00f3stegui JI, Martin TM, Espada G, Scalzi L, Yag\u00fce J, Rosenbaum JT, Modesto C, Cristina Arnal M, Merino R, Garc\u00eda-Consuegra J, Carballo Silva MA, Wouters CH. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a National cohort in Spain. Arthritis Rheum. 2009;60:1797\u2013803. https:\/\/doi.org\/10.1002\/art.24533.","journal-title":"Arthritis Rheum"},{"key":"5987_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng720","volume":"29","author":"C Miceli-Richard","year":"2001","unstructured":"Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, H\u00e4fner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19\u201320. https:\/\/doi.org\/10.1038\/ng720.","journal-title":"Nat Genet"},{"key":"5987_CR11","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1074\/jbc.M008072200","volume":"276","author":"Y Ogura","year":"2001","unstructured":"Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1\/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem. 2001;276:4812\u20138. https:\/\/doi.org\/10.1074\/jbc.M008072200.","journal-title":"J Biol Chem"},{"key":"5987_CR12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jaci.2012.02.004","volume":"129","author":"CE Janssen","year":"2012","unstructured":"Janssen CE, Rose CD, De Hertogh G, Martin TM, Bader Meunier B, Cimaz R, Harjacek M, Quartier P, Ten Cate R, Thomee C, Desmet VJ, Fischer A, Roskams T, Wouters CH. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol. 2012;129:1076\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2012.02.004.","journal-title":"J Allergy Clin Immunol"},{"key":"5987_CR13","doi-asserted-by":"publisher","first-page":"895765","DOI":"10.3389\/fimmu.2022.895765","volume":"13","author":"T Matsuda","year":"2022","unstructured":"Matsuda T, Kambe N, Takimoto-Ito R, Ueki Y, Nakamizo S, Saito MK, Takei S, Kanazawa N. Potential benefits of TNF targeting therapy in Blau syndrome, a NOD2-Associated systemic autoinflammatory granulomatosis. Front Immunol. 2022;13:895765. https:\/\/doi.org\/10.3389\/fimmu.2022.895765.","journal-title":"Front Immunol"},{"key":"5987_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.37776","volume":"65","author":"G Simonini","year":"2013","unstructured":"Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V, Cimaz R. Clinical and transcriptional response to the long-acting interleukin-1 blocker Canakinumab in Blau syndrome-related uveitis. Arthritis Rheum. 2013;65:513\u20138. https:\/\/doi.org\/10.1002\/art.37776.","journal-title":"Arthritis Rheum"},{"key":"5987_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/art.24222","volume":"60","author":"TM Martin","year":"2009","unstructured":"Martin TM, Zhang Z, Kurz P, Ros\u00e9 CD, Chen H, Lu H, Planck SR, Davey MP, Rosenbaum JT. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum. 2009;60:611\u20138. https:\/\/doi.org\/10.1002\/art.24222.","journal-title":"Arthritis Rheum"},{"key":"5987_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1744-313X.2011.00998.x","volume":"38","author":"MC Jimenez-Martinez","year":"2011","unstructured":"Jimenez-Martinez MC, Cruz F, Groman-Lupa S, Zenteno JC. Immunophenotyping in peripheral blood mononuclear cells, aqueous humour and vitreous in a Blau syndrome patient caused by a novel NOD2 mutation. Int J Immunogenet. 2011;38:233\u201342. https:\/\/doi.org\/10.1111\/j.1744-313X.2011.00998.x.","journal-title":"Int J Immunogenet"},{"key":"5987_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.semarthrit.2017.09.010","volume":"47","author":"L Lu","year":"2018","unstructured":"Lu L, Shen M, Jiang D, Li Y, Zheng X, Li Y, Li Z, Zhang L, Tang J, Guo Y, Liu S, Zheng Z, Gao G, Kan Q. Blau syndrome with good reponses to tocilizumab: A case report and focused literature review. Semin Arthritis Rheum. 2018;47:727\u201331. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.010.","journal-title":"Semin Arthritis Rheum"},{"key":"5987_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3899\/jrheum.160672","volume":"44","author":"T Nagakura","year":"2017","unstructured":"Nagakura T, Wakiguchi H, Kubota T, Yamatou T, Yamasaki Y, Nonaka Y, Nerome Y, Akaike H, Takezaki T, Imanaka H, Kawano Y, Takei S. Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome. J Rheumatol. 2017;44:536\u20138. https:\/\/doi.org\/10.3899\/jrheum.160672.","journal-title":"J Rheumatol"},{"key":"5987_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","volume":"57","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Casteele NV. Clinical pharmacokinetics and pharmacodynamics of Infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57:929\u201342. https:\/\/doi.org\/10.1007\/s40262-017-0627-0.","journal-title":"Clin Pharmacokinet"},{"key":"5987_CR20","doi-asserted-by":"publisher","first-page":"692768","DOI":"10.3389\/fphar.2021.692768","volume":"12","author":"H Lu","year":"2021","unstructured":"Lu H, Wang Y, Wang X, Wu X, Zhou L, Lin L, Sheng R, Tian H, Li T, Xu H. Yisaipu(\u00ae) provide AS patients with an economical therapeutic option while original biologicals are more advantageous in the COVID-19 epidemic situation. Front Pharmacol. 2021;12:692768. https:\/\/doi.org\/10.3389\/fphar.2021.692768.","journal-title":"Front Pharmacol"},{"key":"5987_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","volume":"48","author":"D Fouache","year":"2009","unstructured":"Fouache D, Go\u00ebb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, M\u00e9nard JF, Muraine M, Savoye G, Le Lo\u00ebt X, Tharasse C, Vittecoq O. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/kep083.","journal-title":"Rheumatology (Oxford)"},{"key":"5987_CR22","doi-asserted-by":"publisher","first-page":"Cd005468","DOI":"10.1002\/14651858.CD005468.pub2","volume":"Cd005468","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;Cd005468:Cd005468. https:\/\/doi.org\/10.1002\/14651858.CD005468.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"5987_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landew\u00e9 RBM. Safety of synthetic and biological dmards: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101\u201336. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210708.","journal-title":"Ann Rheum Dis"},{"key":"5987_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13075-019-1995-7","volume":"21","author":"C Webers","year":"2019","unstructured":"Webers C, Vanhoof L, Leue C, Boonen A, K\u00f6hler S. Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study. Arthritis Res Ther. 2019;21:215. https:\/\/doi.org\/10.1186\/s13075-019-1995-7.","journal-title":"Arthritis Res Ther"},{"key":"5987_CR25","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862\u20139.https:\/\/doi.org\/10.1002\/1529-0131(200112).","journal-title":"Arthritis Rheum"},{"key":"5987_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/art.21814","volume":"54","author":"IS Shin","year":"2006","unstructured":"Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barr\u00e9 and miller fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006;54:1429\u201334. https:\/\/doi.org\/10.1002\/art.21814.","journal-title":"Arthritis Rheum"},{"key":"5987_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4081\/reumatismo.2019.1115","volume":"71","author":"V Shobha","year":"2019","unstructured":"Shobha V, Desai AM, Matthew T. Etanercept biosimilar associated with Guillain-Barr\u00e9 syndrome: insights from a case. Reumatismo. 2019;71:99\u2013102. https:\/\/doi.org\/10.4081\/reumatismo.2019.1115.","journal-title":"Reumatismo"},{"key":"5987_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0923-2494(97)87239-2","volume":"148","author":"A Cope","year":"1997","unstructured":"Cope A, Ettinger R, McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol. 1997;148:307\u201312. https:\/\/doi.org\/10.1016\/s0923-2494(97)87239-2.","journal-title":"Res Immunol"},{"key":"5987_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1084\/jem.193.4.427","volume":"193","author":"G Kassiotis","year":"2001","unstructured":"Kassiotis G, Kollias G. Uncoupling the Proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193:427\u201334. https:\/\/doi.org\/10.1084\/jem.193.4.427.","journal-title":"J Exp Med"},{"key":"5987_CR30","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1084\/jem.185.9.1573","volume":"185","author":"AP Cope","year":"1997","unstructured":"Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185:1573\u201384. https:\/\/doi.org\/10.1084\/jem.185.9.1573.","journal-title":"J Exp Med"},{"key":"5987_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1586\/14787210.1.4.597","volume":"1","author":"RS Tsang","year":"2003","unstructured":"Tsang RS, Valdivieso-Garcia A. Pathogenesis of Guillain-Barre syndrome. Expert Rev Anti Infect Ther. 2003;1:597\u2013608. https:\/\/doi.org\/10.1586\/14787210.1.4.597.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5987_CR32","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/s0140-6736(72)92439-7","volume":"2","author":"MJ Boyce","year":"1972","unstructured":"Boyce MJ. Virus and the Guillain-Barr\u00e9 syndrome. Lancet. 1972;2:1028\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(72)92439-7.","journal-title":"Lancet"},{"key":"5987_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1471-2334-11-281","volume":"11","author":"T Martelius","year":"2011","unstructured":"Martelius T, Lappalainen M, Palom\u00e4ki M, Anttila VJ. Clinical characteristics of patients with epstein barr virus in cerebrospinal fluid. BMC Infect Dis. 2011;11:281. https:\/\/doi.org\/10.1186\/1471-2334-11-281.","journal-title":"BMC Infect Dis"},{"key":"5987_CR34","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1038\/s41598-022-07260-x","volume":"12","author":"J Olausson","year":"2022","unstructured":"Olausson J, Brunet S, Vracar D, Tian Y, Abrahamsson S, Meghadri SH, Sikora P, Lind Karlberg M, Jakobsson HE, Tang KW. Optimization of cerebrospinal fluid microbial DNA metagenomic sequencing diagnostics. Sci Rep. 2022;12:3378. https:\/\/doi.org\/10.1038\/s41598-022-07260-x.","journal-title":"Sci Rep"},{"key":"5987_CR35","doi-asserted-by":"publisher","first-page":"1055996","DOI":"10.3389\/fmicb.2022.1055996","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhao W, Yang X, Zhang Y, Lin X, Weng X, Wang Y, Cheng C, Chi Y, Wei H, Peng Z, Hu Z. Metagenomic next-generation sequencing for identification of central nervous system pathogens in HIV-infected patients. Front Microbiol. 2022;13:1055996. https:\/\/doi.org\/10.3389\/fmicb.2022.1055996.","journal-title":"Front Microbiol"},{"key":"5987_CR36","doi-asserted-by":"publisher","first-page":"1211240","DOI":"10.3389\/fimmu.2023.1211240","volume":"14","author":"Y Ueki","year":"2023","unstructured":"Ueki Y, Takimoto-Ito R, Saito MK, Tanizaki H, Kambe N. Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome. Front Immunol. 2023;14:1211240. https:\/\/doi.org\/10.3389\/fimmu.2023.1211240.","journal-title":"Front Immunol"},{"key":"5987_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12969-021-00634-x","volume":"19","author":"S Zhang","year":"2021","unstructured":"Zhang S, Cai Z, Mo X, Zeng H. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients. Pediatr Rheumatol Online J. 2021;19:160. https:\/\/doi.org\/10.1186\/s12969-021-00634-x.","journal-title":"Pediatr Rheumatol Online J"},{"key":"5987_CR38","doi-asserted-by":"publisher","first-page":"1759720x2210932","DOI":"10.1177\/1759720x221093211","volume":"14","author":"C \u00c1lvarez-Reguera","year":"2022","unstructured":"\u00c1lvarez-Reguera C, Prieto-Pe\u00f1a D, Herrero-Morant A, S\u00e1nchez-Bilbao L, Mart\u00edn-Varillas JL, Gonz\u00e1lez-L\u00f3pez E, Guti\u00e9rrez-Larra\u00f1aga M, San Segundo D, Demetrio-Pablo R, Ocejo-Vinyals G, Gonz\u00e1lez-Gay MA, Blanco R. Clinical and immunological study of Tofacitinib and baricitinib in refractory Blau syndrome: case report and literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720x221093211. https:\/\/doi.org\/10.1177\/1759720x221093211.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5987_CR39","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.10488","volume":"46","author":"M Cisternas","year":"2002","unstructured":"Cisternas M, Guti\u00e9rrez M, Jacobelli S. Successful Rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the Article by Mohan et al. Arthritis Rheum. 2002;46:3107\u20138. https:\/\/doi.org\/10.1002\/art.10488. author reply 3108\u20133109.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"5987_CR40","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s10067-009-1154-7","volume":"28","author":"A Bouchra","year":"2009","unstructured":"Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol 28 Suppl. 2009;28(Suppl 1):S53-55. https:\/\/doi.org\/10.1007\/s10067-009-1154-7.","journal-title":"Clin Rheumatol 28 Suppl"},{"key":"5987_CR41","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","volume":"40","author":"MC Fern\u00e1ndez-Espartero","year":"2011","unstructured":"Fern\u00e1ndez-Espartero MC, P\u00e9rez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, G\u00f3mez-Reino JJ, Carmona L. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011;40:330\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.06.004.","journal-title":"Semin Arthritis Rheum"},{"key":"5987_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10067-008-1017-7","volume":"28","author":"PT Kurmann","year":"2009","unstructured":"Kurmann PT, Van Linthoudt D, So AK. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol. 2009;28:93\u20134. https:\/\/doi.org\/10.1007\/s10067-008-1017-7.","journal-title":"Clin Rheumatol"},{"key":"5987_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.reuma.2011.01.009","volume":"7","author":"P L\u00f3pez M\u00e9ndez","year":"2011","unstructured":"L\u00f3pez M\u00e9ndez P, Mart\u00edn Santana I, del Pino Reyes M, Y\u00e1nez A, Ruano Hern\u00e1ndez J, Hern\u00e1ndez Beriain M. Herv\u00e1s garc\u00eda, [Meningeal and Guillain-Barr\u00e8 syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy]. Reumatol Clin. 2011;7:401\u20133. https:\/\/doi.org\/10.1016\/j.reuma.2011.01.009.","journal-title":"Reumatol Clin"},{"key":"5987_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.crohns.2011.06.010","volume":"5","author":"M Cesarini","year":"2011","unstructured":"Cesarini M, Angelucci E, Foglietta T, Vernia P. Guillain-Barr\u00e8 syndrome after treatment with human anti-tumor necrosis factor\u03b1 (adalimumab) in a crohn\u2019s disease patient: case report and literature review. J Crohns Colitis. 2011;5:619\u201322. https:\/\/doi.org\/10.1016\/j.crohns.2011.06.010.","journal-title":"J Crohns Colitis"},{"key":"5987_CR45","first-page":"592","volume":"30","author":"S Manganelli","year":"2012","unstructured":"Manganelli S, Rossi M, Tuccori M, Galeazzi M. Guillain-Barr\u00e9 syndrome following adalimumab treatment. Clin Exp Rheumatol. 2012;30:592.","journal-title":"Clin Exp Rheumatol"},{"key":"5987_CR46","first-page":"565","volume":"50","author":"E Soto-Cabrera","year":"2012","unstructured":"Soto-Cabrera E, Hern\u00e1ndez-Mart\u00ednez A, Y\u00e1\u00f1ez H, Carrera R. [Guillain-Barr\u00e9 syndrome. Its association with alpha tumor necrosis factor]. Rev Med Inst Mex Seguro Soc. 2012;50:565\u20137.","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"5987_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/cnd.0000000000000274","volume":"21","author":"EH Yu","year":"2020","unstructured":"Yu EH, Geraldi-Samara D. Pharyngeal-Cervico-Brachial\/Miller fisher overlap syndrome with Infliximab exposure. J Clin Neuromuscul Dis. 2020;21:157\u20138. https:\/\/doi.org\/10.1097\/cnd.0000000000000274.","journal-title":"J Clin Neuromuscul Dis"},{"key":"5987_CR48","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jamaneurol.2015.2251","volume":"72","author":"G Ratnarajan","year":"2015","unstructured":"Ratnarajan G, Thompson A, Dodridge C, Parry A, Elston J. Novel variant of miller fisher syndrome occurring with tumor necrosis factor \u03b1 antagonist therapy. JAMA Neurol. 2015;72:1377\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2015.2251.","journal-title":"JAMA Neurol"},{"key":"5987_CR49","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10067-013-2272-9","volume":"32","author":"B Alvarez-Lario","year":"2013","unstructured":"Alvarez-Lario B, Prieto-Tejedo R, Colazo-Burlato M, Macarr\u00f3n-Vicente J. Severe Guillain-Barr\u00e9 syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. Clin Rheumatol. 2013;32:1407\u201312. https:\/\/doi.org\/10.1007\/s10067-013-2272-9.","journal-title":"Clin Rheumatol"},{"key":"5987_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00365521.2016.1263682","volume":"52","author":"GG Can\u00e7ado","year":"2017","unstructured":"Can\u00e7ado GG, Vilela EG. Guillain-Barr\u00e9 syndrome during adalimumab therapy for crohn\u00b4s disease: coincidence or consequence? Scand J Gastroenterol. 2017;52:473\u20136. https:\/\/doi.org\/10.1080\/00365521.2016.1263682.","journal-title":"Scand J Gastroenterol"},{"key":"5987_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1590\/abd1806-4841.20175871","volume":"92","author":"NB Natividade","year":"2017","unstructured":"Natividade NB, Felix PAO, Lerer C. Guillain-Barr\u00e9 syndrome in a patient on adalimumab for the treatment of psoriasis. Bras Dermatol. 2017;92:85\u20137. https:\/\/doi.org\/10.1590\/abd1806-4841.20175871.","journal-title":"Bras Dermatol"},{"key":"5987_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-017-3179-z","volume":"39","author":"JH Lee","year":"2018","unstructured":"Lee JH, Park JS, Park D. Successful IVIG treatment without discontinuation of TNF-\u03b1 blocker in Guillain-Barre syndrome induced by adalimumab in patient with crohn\u2019s disease. Neurol Sci. 2018;39:595\u20138. https:\/\/doi.org\/10.1007\/s10072-017-3179-z.","journal-title":"Neurol Sci"},{"key":"5987_CR53","doi-asserted-by":"publisher","unstructured":"Patwala K, Crump N, De Cruz P. Guillain-Barr\u00e9 syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity. BMJ Case Rep. 2017;2017. https:\/\/doi.org\/10.1136\/bcr-2017-219481.","DOI":"10.1136\/bcr-2017-219481"},{"key":"5987_CR54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.33588\/rn.6506.2017115","volume":"65","author":"FJ Alberola-Amores","year":"2017","unstructured":"Alberola-Amores FJ, Navarro-Canto L, Gonzalez-Ferrandez JA. [Miller fisher syndrome following treatment with certolizumab in a patient with rheumatoid arthritis]. Rev Neurol. 2017;65:286\u20138.","journal-title":"Rev Neurol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05987-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05987-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05987-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:18:27Z","timestamp":1770203907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-025-05987-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5987"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05987-w","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection and usage of the clinical information for research purpose were approved by Shanghai Children\u2019s Medical Center Ethical Committee. The approval number is SCMCIRB-2025059-1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s parents for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}